Comprehensive interpretation of RCC abstracts, ASCO-GU 23
10.3760/cma.j.cn112330-20230327-00001
- VernacularTitle:2023 ASCO-GU肾癌精粹解读
- Author:
Zhenhua LIU
1
;
Xinan SHENG
;
Hao ZENG
Author Information
1. 四川大学华西医院泌尿外科，成都 610041
- Keywords:
Carcinoma, Renal cell;
American Society of Clinical Oncology-genitourinary cancer symposium(ASCO-GU);
Target therapy;
Immunotherapy;
Biomarker
- From:
Chinese Journal of Urology
2023;44(4):245-247
- CountryChina
- Language:Chinese
-
Abstract:
The ASCO-GU 23 conference was held offline as scheduled after the pandemic. A total of 167 abstracts in the field of renal cell carcinoma has been posted during the conference, covering the first PET/CT diagnostic technology targeting tumors in renal cell carcinoma, risk stratified interpretation of the previous clinical trial results, and exploring the value of tumor and serum biomarkers for precise classification therapy, as well as providing evidence for the therapeutic scheme sequencing.
